Table 3.

Risk for all-cause death, CVE, sudden death, stroke, and MI by quartiles of baseline PF4-H-ABs

ParameterQuartile 1 ≤0.208 PF4-H-ABs (n = 310)Quartile 2 >0.208 to ≤0.268 PF4-H-ABs (n = 309)Quartile 3 >0.268 to ≤0.362 PF4-H-ABs (n = 309)Quartile 4 >0.362 PF4-H-ABs (n = 308)
All-cause death
    no. of events during study152152142159
    adjusted HR (95% CI)ab1.27 (1.01 to 1.59)1.12 (0.88 to 1.41)1.27 (1.02 to 1.60)
    P0.050.360.04
CVE (MI, cardiac death, and stroke)
    no. of events during study120108107125
    adjusted HR (95% CI)ab1.12 (0.86 to 1.46)1.07 (0.82 to 1.39)1.28 (1.00 to 1.66)
    P0.410.620.06
MI
    no. of events during study55454455
    adjusted HR (95% CI)ab0.97 (0.65 to 1.45)0.96 (0.64 to 1.44)1.23 (0.84 to 1.79)
    P0.890.850.29
Sudden death
    no. of events during study39314049
    adjusted HR (95% CI)ab0.98 (0.61 to 1.57)1.12 (0.72 to 1.75)1.50 (0.98 to 2.30)
    P0.920.620.06
Stroke
    no. of events during study29261824
    adjusted HR (95% CI)ab1.11 (0.65 to 1.90)0.75 (0.41 to 1.36)0.94 (0.55 to 1.63)
    P0.700.340.84
  • a Explanatory variables were selected by a stepwise process (atorvastatin treatment was always included in the final model) with adjustment for treatment assignment (was always included in the final model), gender, age, phosphate, LDL, hemoglobin, glycated hemoglobin (HbA1c), CRP, ever smoked, systolic and diastolic BP, body mass index, ultrafiltration volume, duration of dialysis, hemodialysis shunt, history of stroke/transient ischemic attack, coronary artery disease (MI, coronary artery bypass grafting, percutaneous coronary intervention, and angiographically documented coronary artery disease), arrhythmia, peripheral vascular disease, and congestive heart failure (predominantly New York Heart Association class II).

  • b The first quartile was used as the reference for each of the other three.